Champions Oncology (NASDAQ:CSBR) released its quarterly earnings data on Monday. The biotechnology company reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by ($0.01), Fidelity Earnings reports. Champions Oncology had a negative return on equity of 35.57% and a negative net margin of 3.60%.
Shares of CSBR stock opened at $8.28 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock has a 50 day simple moving average of $8.57 and a 200-day simple moving average of $8.21. Champions Oncology has a 1-year low of $4.02 and a 1-year high of $10.89.
Separately, Zacks Investment Research lowered Champions Oncology from a “buy” rating to a “hold” rating in a research report on Friday, June 26th.
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.